Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19918206 | 0.87 | BCHE (0.45) | SNCACNR1CNR2BCHEALDH1A1 | |
| SCHEMBL29403748 | 0.87 | BCHE (0.45) | SNCACNR1CNR2BCHEALDH1A1 | |
| SCHEMBL19900765 | 0.82 | SNCA (0.46) | SNCACNR2BCHEKDM4ETP53 | |
| SCHEMBL17999651 | 0.81 | SNCA (0.45) | SNCACNR2BCHEKDM4ETP53 | |
| SCHEMBL19900767 | 0.79 | MAPK1 (0.48) | SNCABCHEKDM4ETP53MAPK1 | |
| SCHEMBL19939646 | 0.79 | BCHE (0.47) | SNCABCHEKDM4ETP53MAPK1 | |
| SCHEMBL19942820 | 0.74 | BCHE (0.49) | SNCABCHEKDM4ETP53MAPK1 | |
| SCHEMBL3631474 | 0.74 | GAA (0.68) | CNR1CNR2BCHEKDM4EMAPK1 | |
| SCHEMBL11338984 | 0.74 | GAA (0.68) | CNR1CNR2BCHEKDM4EMAPK1 | |
| SCHEMBL11335452 | 0.74 | GAA (0.68) | CNR1CNR2BCHEKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295101-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-09-21 | — | — | US | disclosed |
| US-11560360-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220081404-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-03-17 | — | — | US | disclosed |
| US-11034662-B2 | Substituted phenothiazines as mitochondrial agents | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200407333-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-12-31 | — | — | US | disclosed |
| EP-3258938-B1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | UNIV ARIZONA STATE (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10745366-B2 | Therapeutic compounds | ARIZON BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200115355-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-04-16 | — | — | US | disclosed |
| US-10472340-B2 | Substituted phenothiazines as mitochondrial agents | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190185441-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-06-20 | — | — | US | disclosed |
| US-20180065941-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-08 | — | — | US | disclosed |
| WO-2018039487-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-3258938-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | Arizona Board of Regents on behalf of Arizona State University (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016133995-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065941-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | GSR, COQ8A, TXNRD2 | SNCA 766/4885CNR1 3750/4885CNR2 3654/4885 |
| US-20200115355-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | GSR, COQ8A, TXNRD2 | SNCA 766/4885CNR1 3750/4885CNR2 3654/4885 |
| US-10472340-B2 | Substituted phenothiazines as mitochondrial agents | GSR, TXN2, PCK2 | SNCA 584/4885CNR1 3729/4885CNR2 3432/4885 |
| US-20200407333-A1 | THERAPEUTIC COMPOUNDS | CFTR, MC2R, RPS21 | SNCA 1861/4885CNR1 362/4885CNR2 1055/4885 |
| US-11560360-B2 | Therapeutic compounds | CFTR, MC2R, RPS21 | SNCA 1861/4885CNR1 362/4885CNR2 1055/4885 |
| US-20230295101-A1 | THERAPEUTIC COMPOUNDS | CFTR, C1R, FURIN | SNCA 2990/4885CNR1 405/4885CNR2 1023/4885 |
| US-11034662-B2 | Substituted phenothiazines as mitochondrial agents | GSR, SQOR, MT-ATP6 | SNCA 585/4885CNR1 1360/4885CNR2 1903/4885 |
| US-20190185441-A1 | THERAPEUTIC COMPOUNDS | CFTR, C1R, FURIN | SNCA 2990/4885CNR1 405/4885CNR2 1023/4885 |
| US-10745366-B2 | Therapeutic compounds | CFTR, C1R, FURIN | SNCA 2990/4885CNR1 405/4885CNR2 1023/4885 |
| US-20220081404-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | GSR, COQ8A, TXNRD2 | SNCA 766/4885CNR1 3750/4885CNR2 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.